Research
Hormonal
Dual agonists improve glycemic control and promote substantial weight loss.
Practitioners can consider dual agonists as effective options for improving glycemic control and aiding weight loss in patients with metabolic diseases.
StrongSupportsmedium confidence
The review explores how dual agonists improve glycemic control, promote substantial weight loss, and modify cardiometabolic risk factors.
Why this rating
The claim is supported by qualitative thematic evidence from major clinical trials.
Source
Emerging Role of Dual Agonists in Metabolic Disease Management: Clinical Outcomes and Safety Considerations – A Review Study
Akter Sraboni et al. · Review of Medicine Surgery and Dentistry · 2026
DOI 10.64907/xkmf.v5.i1.rmsd.1
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →